120
Participants
Start Date
February 10, 2022
Primary Completion Date
January 31, 2026
Study Completion Date
March 31, 2026
Sliding Scale Insulin
After antenatal corticosteroid administration, women will continue to receive long- and short-acting subcutaneous insulin injections as prescribed at home. In addition, they will receive supplemental short-acting insulin using a sliding scale based on postprandial glucose values. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
Up-Titration of Home Insulin
After antenatal corticosteroid administration, women will receive long- and short-acting subcutaneous insulin injections at increased dosages compared to that prescribed at home. Insulin will be increased by 30% on the day that they receive their 1st dose of antenatal corticosteroids (day 1), 50% on day 2, 50% on day 3, 30% on day 4, and 15% increase on day 5. On day 6 they will return to their home insulin regimen. Capillary blood glucose values will be measured with fingersticks 4 times daily (fasting and 1-hour postprandial).
Continuous Insulin Infusion
After antenatal corticosteroid administration, women will discontinue their home insulin regimen and be placed on a continuous insulin infusion with insulin boluses and titration of infusion rate per institutional L\&D protocol. Capillary blood glucose values will be measured with fingersticks every hour.
Dexcom G6 Professional Continuous Glucose Monitor
Masked Dexcom G6 Pro devices will be worn for 10 days.
RECRUITING
University of South Carolina Greenville / Prisma Health-Upstate, Greenville
RECRUITING
University of Alabama at Birmingham, Birmingham
RECRUITING
University of Texas Health Science Center at Houston, Houston
RECRUITING
Oregon Health and Science University, Portland
University of Alabama at Birmingham
OTHER